#ESMO2026 | Drugging the Undruggable: A New Era in Precision Oncology
“Undruggable” was never about the target. It was about our tools.
An inspiring presentation by Dr. Vivek Subbiah (@VivekSubbiah) at ESMO 2026, highlighting how previously untargetable cancer drivers are becoming therapeutically actionable.
From KRAS inhibition and p53 reactivation to MYC targeting, protein degradation, synthetic lethality, and AI-driven drug discovery, precision oncology is entering a new era.
The next challenge is not only developing new drugs, but identifying the right molecular target in the right patient.
Comprehensive genomic profiling and ctDNA testing will play an increasingly important role in this transformation.
#ESMO26 @myESMO @VivekSubbiah #PrecisionOncology #UndruggableTargets #KRAS #TP53 #GenomicTesting #LiquidBiopsy @Dr_R_Kurzrock
34 views · 1 like · 0 reposts · 0 replies
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgSource: Prof. Dr. Ahmet Dirican · x.com